Expanded RAS Mutation Testing in mCRC

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.